Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

ANIX Anixa Biosciences Inc

Price (delayed)

$2.84

Market cap

$91.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.38

Enterprise value

$89.79M

Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type ...

Highlights
The debt has increased by 48% YoY but it has decreased by 3.9% from the previous quarter
The net income has declined by 4.6% year-on-year but it has increased by 2.8% since the previous quarter
The company's quick ratio fell by 41% YoY and by 4.2% QoQ
The equity has contracted by 32% YoY and by 10% from the previous quarter

Key stats

What are the main financial stats of ANIX
Market
Shares outstanding
32.21M
Market cap
$91.48M
Enterprise value
$89.79M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$13.14M
Net income
-$12.13M
EBIT
-$12.13M
EBITDA
-$12.1M
Free cash flow
-$7.98M
Per share
EPS
-$0.38
EPS diluted
-$0.38
Free cash flow per share
-$0.25
Book value per share
$0.5
Revenue per share
$0
TBVPS
$0.53
Balance sheet
Total assets
$16.98M
Total liabilities
$2.07M
Debt
$221,000
Equity
$16.07M
Working capital
$14.88M
Liquidity
Debt to equity
0.01
Current ratio
8.89
Quick ratio
8.27
Net debt/EBITDA
0.14
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-60.4%
Return on equity
-64.1%
Return on invested capital
-72%
Return on capital employed
-80.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIX stock price

How has the Anixa Biosciences stock price performed over time
Intraday
1.79%
1 week
8.81%
1 month
1.07%
1 year
13.6%
YTD
22.41%
QTD
-0.7%

Financial performance

How have Anixa Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.14M
Net income
-$12.13M
Gross margin
N/A
Net margin
N/A
The net income has declined by 4.6% year-on-year but it has increased by 2.8% since the previous quarter
ANIX's operating income is up by 3.4% since the previous quarter

Price vs fundamentals

How does ANIX's price correlate with its fundamentals

Growth

What is Anixa Biosciences's growth rate over time

Valuation

What is Anixa Biosciences stock price valuation
P/E
N/A
P/B
5.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ANIX's EPS is down by 2.7% year-on-year but it is up by 2.6% since the previous quarter
The equity has contracted by 32% YoY and by 10% from the previous quarter
The price to book (P/B) is 19% higher than the 5-year quarterly average of 4.8 and 7% higher than the last 4 quarters average of 5.3

Efficiency

How efficient is Anixa Biosciences business performance
Anixa Biosciences's return on invested capital has decreased by 38% YoY and by 9% QoQ
The return on equity has declined by 36% year-on-year and by 7% since the previous quarter
The company's return on assets fell by 33% YoY and by 6% QoQ

Dividends

What is ANIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIX.

Financial health

How did Anixa Biosciences financials performed over time
The company's quick ratio fell by 41% YoY and by 4.2% QoQ
The current ratio has declined by 38% year-on-year and by 4.9% since the previous quarter
The debt is 99% less than the equity
The debt has increased by 48% YoY but it has decreased by 3.9% from the previous quarter
The equity has contracted by 32% YoY and by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.